The probiotic effect of Saccharomyces boulardii in a pediatric age group.
The aim of this study was to determine the efficacy of S. boulardii in diarrhea associated with commonly used antibiotics such as sulbactam-ampicillin (SAM) and azithromycin (AZT). Four hundred and sixty-six patients were assigned to four different groups as follows: group 1:117 patients receiving SAM alone; group 2:117 patients receiving SAM and S. boulardii, group 3:105 patients receiving AZT alone; group 4:127 patients receiving AZT and S. boulardii. Antibiotic-associated diarrhea was seen in 42 of the 222 patients (18.9 per cent) receiving an antibiotic without the probiotic, and in 14 of the 244 patients (5.7 per cent) who received both the probiotic and the antibiotic (p < 0.05). In the group receiving SAM where S. boulardii use was found to be significant, the use of S. boulardii decreased the diarrhea rate from 32.3 to 11.4 per cent in the 1-5 years age group (p < 0.05). This is a pioneering study investigating combined antibiotic and probiotic use in pediatric diarrhea patients.
Erdeve
Omer
O
Ankara Education and Research Hospital, Ankara, Turkey. omererdeve@yahoo.com
Tiras
Ulku
U
Dallar
Yildiz
Y
D000293:Adolescent; D000667:Ampicillin / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D017963:Azithromycin / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D003967:Diarrhea / Q000139:chemically induced / Q000517:prevention & control*; D004338:Drug Combinations; D006801:Humans; D007223:Infant; D019936:Probiotics / Q000627:therapeutic use*; D012440:Saccharomyces; D013407:Sulbactam / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D000667:Ampicillin; D017963:Azithromycin; D013407:Sulbactam